Interactive Virtual Presentation

Smoother Waters Ahead? New Directions in the Management of HCV

Source: Smoother Waters Ahead? New Directions in the Management of HCV*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Smoother Waters Ahead? New Directions in the Management of HCV

Program Director: Stefan Zeuzem, MD

Faculty:

Nezam H. Afdhal, MD, FRCPI
Ira M. Jacobson, MD
Jean-Michel Pawlotsky, MD, PhD

CREDIT INFORMATION

Release Date: 12/18/09

Expiration Date: 12/17/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing contact hour

Status: Please log in to view status

Begin the Interactive Virtual Presentation

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe 2 factors that impact the current and/or future burden of HCV disease
Identify STAT-C agents that are currently in advanced clinical development, including their mechanisms of action
Compare the duration of therapy required by the current standard of care with emerging data from studies of STAT-Cs in treatment-naive and treatment-experienced patient populations
Compare the efficacy of current FDA-approved regimens and emerging data from studies of STAT-Cs in both treatment-naive and treatment-experienced patient populations

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.